Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia
Authors:
- Carlos A. Torres-DuqueCTCarlos A. Torres-Duque
- REXACOL ConsortiumRCREXACOL Consortium
- Juliana Proaños-JuradoJPJuliana Proaños-Jurado
Open Access
- 28 November 2022
- journal article
- research article
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 22 (1) , 1-10
Abstract
Background: The allergic phenotype is responsible for more than 50% of severe asthma cases. In a stepwise approach, add-on treatments such as anti-IgE are used for severe allergic asthma (SAA). This study was aimed to describe the real-world effectiveness of omalizumab in adult and pediatric patients with SAA in Colombia.Methods: This was an observational, non-interventional, retrospective study. Data from patients with SAA that received at least one month of treatment with omalizumab was obtained from medical records at eight sites in Colombia. Time-zero (t − 0) was defined as the date of initiation of omalizumab, and data was gathered for a 12-month period before t − 0 and a 12-month period after t − 0. Clinical outcomes, including exacerbations, were assessed at 6 and 12 months. Effectiveness of omalizumab was evaluated in terms of the reduction of the risk of exacerbations (annualized rate).Results: We included 143 patients with SAA. There was a decrease of 72.4% of the annualized rate of clinically significant asthma exacerbations during the year after omalizumab (from 1.74 before to 0.48 after) with a substantial reduction of the risk of exacerbations by 56.7% (RR [95% CI] 0.43 [0.30–0.63]p < 0,001).Conclusion: The use of omalizumab in Colombia as a treatment for SAA notably reduced the risk of clinically significant exacerbations. This study is the first to evaluate omalizumab real-life effectiveness in pediatric and adult patients in the country.Keywords
Funding Information
- Novartis de Colombia S.A.
This publication has 42 references indexed in Scilit:
- The prevalence of severe refractory asthmaJournal of Allergy and Clinical Immunology, 2015
- Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in ItalyPulmonary Pharmacology & Therapeutics, 2015
- Omalizumab for asthma in adults and childrenCochrane Database of Systematic Reviews, 2014
- International ERS/ATS guidelines on definition, evaluation and treatment of severe asthmaEuropean Respiratory Journal, 2013
- Prevalence of asthma and other allergic conditions in Colombia 2009–2010: a cross-sectional studyBMC Pulmonary Medicine, 2012
- Efficacy and Safety of Subcutaneous Omalizumab vs Placebo as Add-on Therapy to Corticosteroids for Children and Adults With AsthmaChest, 2011
- Immunoglobulin E: Role in asthma and allergic disease: Lessons from the clinicPharmacology & Therapeutics, 2007
- Management of asthma with anti-immunoglobulin E: A review of clinical trials of omalizumabRespiratory Medicine, 2006
- Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATEAllergy, 2004
- The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthmaEuropean Respiratory Journal, 2003